According to The Insight Partners' research, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market was valued at US$ 90.3 Million in 2024 and is expected to reach US$ 434.1 Million by 2031, registering a CAGR of 25.3% from 2025 to 2031.
Increasing clinical trials for innovative therapies and increasing research and access to specialized facilities and technologies are among the critical factors attributed to driving the Middle East & Africa cell and gene therapy contract development and manufacturing organization market growth.
TCell and gene therapies require highly specialized manufacturing processes, including the production of viral vectors, transduced cells, and other specialized biological materials. These therapies often target rare or complex diseases, such as genetic disorders, cancer, and autoimmune diseases. As of 2024, there were approximately 1,975 ongoing clinical trials for cell and gene therapies (CGTs), marking a pivotal year for approvals, with hundreds more in the pipeline, creating the demand for contract development and manufacturing organizations (CDMOs).
The increasing number of biotech startups and biopharmaceutical companies entering the gene and cell therapy field has propelled the demand for CDMOs. Biopharmaceutical companies, especially small and medium-sized enterprises, lack the infrastructure and expertise required for manufacturing these highly specialized therapies. Consequently, they turn to CDMOs for their comprehensive expertise in managing clinical trial production, ensuring regulatory compliance, and scaling up manufacturing processes. The Autologus Therapeutics and AGC Biologics Milan Partnership started in 2020 when the company was involved in the development, manufacturing, and supply of viral vectors for Autolus' obe-cel CAR-T product candidate, AUCATZYL. The collaboration between the two parties was instrumental in bringing the therapy to market in a timely manner. Technological advancements such as artificial intelligence (AI) optimize manufacturing processes for clinical trials. These innovations enable more efficient and cost-effective production methods, which are critical based on the complexities involved. Therefore, increasing clinical trials for innovative therapies, along with increasing demand for CDMOs for increasing research, development, and commercialization, drive the growth of the cell and gene therapy contract development and manufacturing organization market.
On the contrary, the high manufacturing complexities hamper the growth of the Middle East & Africa cell and gene therapy contract development and manufacturing organization market.
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation Analysis:
- By Service Type, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Drug Development and Manufacturing, Testing and Regulatory Services, and Others. The Drug Development and Manufacturing segment is projected to expand at 25.9% CAGR during 2025 - 2031.
- By Product Type, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Gene Therapy and Cell Therapy. The Gene Therapy segment is projected to expand at 26.0% CAGR during 2025 - 2031.
- By End User, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others. The Biopharmaceutical Companies segment is projected to expand at 26.4% CAGR during 2025 - 2031.
By country, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is categorized into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa is projected to expand at 26.0% CAGR during 2025 - 2031.
Key players operating in the Cell and Gene Therapy Contract Development and Manufacturing Organization Market are Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK Pharmteco Inc., among others.
- In March 2025, WuXi Biologics Launched EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production. EffiX is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe. EffiX delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
- In April 2025, Thermo Fisher Scientific Inc. announced the 5L DynaDrive Single-Use Bioreactor (S.U.B.), designed to meet the evolving needs of modern bioprocessing. The 5L DynaDrive expands the company's robust portfolio of bioreactors, offering seamless scalability from 1 to 5,000 liters and accelerating bench-scale process development. It also facilitates the cost-effective transition from bench to commercialization with consistent reactor design and film across all scales.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com